anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Interventions that support disease self-management (further referred to as 'self-management interventions') can have a significant impact on the health and quality of life of patients suffering from chronic conditions in general and chronic kidney disease (CKD) patients in specific. In the last decade, the use of electronic health (eHealth) technology in self-management interventions has become more and more popular. EHealth-based self-management interventions have been shown to improve health-related outcomes, such as blood pressure (BP) control and medication adherence, and found to be feasible and acceptable for CKD patients and care professionals. Hence, the use of eHealth self-management interventions for CKD patients has become increasingly popular. Knowledge of the implementation and effectivity of such interventions in China and other developing countries is, however, still lacking. Researchers from the Leiden University Medical Center (LUMC) developed 'Medical Dashboard', an eHealth intervention to help support and involve CKD patients in their disease self-management. We aim to tailor the evidence-based Dutch intervention 'Medical Dashboard' to the Chinese context and evaluate its implementation process and effectiveness.
The study design is a randomized double-blind cross over clinical trial. Patients who meet inclusion criteria and no exclusion criteria will be enrolled. They will undergo a baseline cardiovascular assessment including echocardiography, magnetic resonance imaging or magnetic resonance angiography (MRI/MRA), serum blood samples, brachial artery reactivity testing, and carotid intimal media thickness testing. Once they have completed their baseline testing, they will be randomized to either atorvastatin 80mg or placebo. They will complete 12 weeks of therapy and return at the end of 12 weeks to have a repeat brachial artery study and serum studies. There will then be a four week washout period where they take no medication. They will return for a follow up visit at the end of that four week period for repeat baseline brachial artery testing and serum studies. They then will be assigned to the opposite agent they were on previously (so if they originally were on placebo they switch to atorvastatin and vice versa). They will complete another 12 weeks of therapy and return at the end for a final brachial artery study and blood testing.
603980 The disclosure relates to a process for the preparation of 1-hexadecyl-2-(4’-carboxy)butylglycerol and 1-hexadecyl-2-(4’-carboxy)butyl-glycero-3-phosphocholine compounds which comprises: reacting a first compound having a glycerolic backbone, wherein a hydroxyl group at position sn-3 of the glycerolic backbone is protected with a trityl group, with a second compound having an unsaturated bond and having the formula Br(CH2)4CHCH2, to obtain a third compound. providing the solution of said third compound, removing insoluble impurities from said solution to obtain a purified third compound. reacting said purified third compound with a mixture of periodate and permanganate to form an intermediate compound. removing said trityl group thereby forming said 1-hexadecyl-2-(4’-carboxy)butyl-glycerol Isolating the resulting compound through phase separation. Where 1-hexadecyl-2-(4’-carboxy)butyl-glycero-3-phosphocholine is to be prepared the process further comprises: reacting the isolated 1-hexadecyl-2-(4’-carboxy)butyl-glycerol via a methyl ester compound with POCl3, thereby forming the compound having a reactive phosphorous containing group attached to the glycerolic backbone, and converting the reactive phosphorous-containing group to a phosphorus containing moiety to form a compound incorporating a phosphocholine moiety, hydrolyzing said methyl ester moiety of said compound incorporating a phosphocholine moiety thereby forming said 1-hexadecyl-2-(4’-carboxy)butyl-glycero-3-phosphocholine. The solvent for step (ii) may be hexane, step (viii) may be achieved using Lithium Hydroxide(LiOH). Compounds and intermediates are also disclosed.
PURPOSE:An insecticide and controlling agent containing a specific pyrethroid compound as an agricultural chemical as an active constituent and effective against ectoparasites and injurious insects, e.g. mites, flies, fleas, etc., of animals other than humans. CONSTITUTION:An insecticide and controlling agent containing a pyrethroid compound expressed by formula I (X is Cl or Br) as an active constituent. Although it is well known that the compound expressed by formula I is effective against sanitary injurious insects, e.g. flies, mosquitoes, etc., and agricultural injurious insects, e.g. planthoppers or leafhoppers, etc., the compound expressed by formula I is found to have high insecticidal and controlling effect on ectoparasites, e.g. mites, fleas, lice, etc. The insecticide and controlling agent may be applied by a direct method, e.g. pouring on or spot on of the animal skin area or indirect method, e.g. ear tag or necklace, etc. The effect thereof is equal to that of a compound expressed by formula II (R1 and R2 are independent halogen; R3 is H or CN). The toxicity is low without allergic disorder.
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. The major cause of vision loss in this disease is due to the development of choroidal neovascular membrane formation (CNVM). Several clinical trials have proven that eyes with "well-defined" CNVM or lesions that can be readily demarcated with fluorescein angiography can be successfully treated with laser photocoagulation. However, up to 87% of eyes present with "ill-defined" CNVM or lesions that cannot be well demarcated on fluorescein angiography and are not amenable to laser photocoagulation. No beneficial treatment for this form of choroidal neovascularization has been established.

Histopathologic study has demonstrated the presence of inflammatory and reparative responses in the retina of patients with ill-defined choroidal neovascularization. Since corticosteroids have been shown to downregulate many of the cellular factors involved in both inflammation and repair, the present study is designed to assess the ability of corticosteroid injection around the eye to prevent severe vision loss associated with "ill-defined" choroidal neovascularization in the setting of age-related macular degeneration. The study will be organized as a randomized open label control clinical trial involving 2 phases. Phase 1 involving 40 patients will establish the feasibility and safety of this treatment modality. Phase 2 will place emphasis on efficacy of the study.
BACKGROUND: Hibiscus syriacus L. is a deciduous shrub with a strong environmental resistance and wide application prospects. The genetic background and ploidy levels of Hibiscus cultivars are complex, and polyploid breeding has long been an important method for developing new Hibiscus cultivars. However, the relationship of ploidy levels with leaf morphology, stomatal characteristics, and leaf anatomy remains unclear.
RESULTS: This study analyzed three ploidy levels (triploid, tetraploid, and hexaploid) of Hibiscus syriacus. Flow cytometry confirmed the ploidy levels, and morphological traits were evaluated. Leaf length, leaf width, and petiole length decreased with increasing ploidy. Stomatal length, stomatal width, guard cell length, and guard cell width increased and stomatal number and density decreased with increasing ploidy. The hexaploids exhibited the highest midrib diameter and palisade tissue thickness values. Correlation analyses revealed that stomatal morphology served as a reliable marker for determining ploidy levels.
CONCLUSION: This study highlights the impact of varying ploidy levels on the leaf and stomatal morphologies and leaf anatomy of Hibiscus syriacus. These findings can provide theoretical guidance for improving Hibiscus cultivars in terms of stress resistance, adaptability, and ornamental traits, and for developing new cultivars with enhanced characteristics. Future research should focus on utilizing these morphological markers to optimize breeding strategies for Hibiscus cultivars.
BACKGROUND: Aspirin, an effective, low-cost pharmaceutical, can significantly reduce mortality if used promptly after acute myocardial infarction (AMI). However, many AMI survivors do not receive aspirin within a few hours of symptom onset. Our aim was to quantify the mortality benefit of self-administering aspirin at chest pain onset, considering the increased risk of bleeding and costs associated with widespread use.
METHODS AND RESULTS: We developed a population simulation model to determine the impact of self-administering 325 mg aspirin within 4 hours of severe chest pain onset. We created a synthetic cohort of adults ≥ 40 years old experiencing severe chest pain using 2019 US population estimates, AMI incidence, and sensitivity/specificity of chest pain for AMI. The number of annual deaths delayed was estimated using evidence from a large, randomized trial. We also estimated the years of life saved (YOLS), costs, and cost per YOLS. Initiating aspirin within 4 hours of severe chest pain onset delayed 13 016 (95% CI, 11 643-14 574) deaths annually, after accounting for deaths due to bleeding (963; 926-1003). This translated to an estimated 166 309 YOLS (149391-185 505) at the cost of $643 235 (633 944-653 010) per year, leading to a cost-effectiveness ratio of $3.70 (3.32-4.12) per YOLS.
CONCLUSIONS: For <$4 per YOLS, self-administration of aspirin within 4 hours of severe chest pain onset has the potential to save 13 000 lives per year in the US population. Benefits of reducing deaths post-AMI outweighed the risk of bleeding deaths from aspirin 10 times over.
The control group will receive usual care. Patients will be instructed to perform respiratory exercises 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. Respiratory exercises include using incentive spirometry and exercises for deep breathing, huffing and coughing. Patients receive a leaflet with the exercises described and the exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
Climbing fibers, connecting the inferior olive and Purkinje cells, form the nervous system's strongest neural connection. These fibers activate after critical events like motor errors or anticipation of rewards, leading to bursts of excitatory postsynaptic potentials (EPSPs) in Purkinje cells. The number of EPSPs is a crucial variable when the brain is learning a new motor skill. Yet, we do not know what determines the number of EPSPs. Here, we measured the effect of nucleo-olivary stimulation on periorbital elicited climbing fiber responses through in-vivo intracellular Purkinje cell recordings in decerebrated ferrets. The results show that while nucleo-olivary stimulation decreased the probability of a response occurring at all, it did not reduce the number of EPSPs. The results suggest that nucleo-olivary stimulation does not influence the number of EPSPs in climbing fiber bursts.
The present invention discloses medicine for treating hyperosteogeny, which uses more than 30 kinds of traditional Chinese medicine comprising matrimony vine, large-leaf gentian root, panax notoginseng, hemlock parsley, sappan wood, monkshood root, cassia twig, north notoginseng, black-tail snake, notopterygium root, etc. as raw materials. The medicine is decocted by adding honey, crystal sugar and white spirits. A patient can drink 20 ml of the medicine every time for three times per day. A treatment course has a month. The patient can continuously drink the medicine for more than 3 treatment courses. The present invention has the characteristics that the medicine can nourish the liver and the kidney, strengthen tendons and bones, activate blood circulation, dissipate blood stasis, eliminate evil and dredge collaterals for alleviating pain, and can effectively promote bone calcification, etc.
PURPOSE: A pharmaceutical composition containing basic fibroblast growth factor(bFGF) for treating or preventing chronic obstructive pulmonary disease(COPD) and asthma is provided to ensure same effect with intravenous infusion or subcontaneous administration. CONSTITUTION: A pharmaceutical composition for treating or preventing chronic obstructive pulmonary disease(COPD) and asthma contains basic fibroblast growth factor(bFGF) as an active ingredient. A daily dose of the bFGF is 0.015~600ng. When the composition is liquid and the composition is transferred to lung through nebulizer. When the composition is suspension, the composition is transferred to lung through a metered dose inhaler. When the composition is dried powder, the composition is delivered to lung through dried powder inhaler.
Repeated administration of ACTIMMUNE to patients with advanced hepatic disease may result in accumulation of interferon gamma-1b. Frequent assessment of liver function in these patients is recommended.

Elevations of aspartate transaminase (AST) and/or alanine transaminase (ALT) (up to 25-fold) have been observed during ACTIMMUNE therapy. The incidence appeared to be higher in patients less than 1 year of age compared to older children. The transaminase elevations were reversible with reduction in dosage or interruption of ACTIMMUNE treatment. Patients begun on ACTIMMUNE before age one year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified [see Dosage and Administration (2.3)].
A composition which is a cream or lotion for topical application to human skin. The composition includes emu oil as a component. Emu oil is generally comprised of myristic acid, palmitic acid, palmitoleic acid, margaric acid, stearic acid, elaidic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidic acid and eicosenoic acid. The composition also includes a medically active component, such as lactic acid or some other alpha-hydroxy acid. The balance of the components of the composition are water, glycerin, and an emulsion base. Liposomes may be included in the composition. The composition provides for increased skin penetrability due to the emu oil.
Severe obesity is a contributor to adverse perinatal outcomes and Black females are disproportionately burdened. The prevalence of severe obesity is on the rise in the United States (U.S.), having increased from 6.4% of the adult population in 2011-2012 to just over 9% of adults in 2017-2018. The prevalence of severe obesity among reproductive age females is approximately 10%. This is an alarming statistic given severe obesity is a predictor of adverse perinatal outcomes including gestational diabetes mellitus, preeclampsia, premature birth (both spontaneous and medically indicated), and at its most severe, fetal death, birth defects, and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. Existing lifestyle interventions (calorie control/dietary pattern changes/physical activity) have showed modest effects on attenuating excess gestational weight gain and modest effects on perinatal health outcomes among pregnant females with obesity. Time- restricted eating, where an individual simply watches the clock and consumes calories within a particular eating window, is a simple and highly accessible eating pattern that has the potential to minimize gestational weight gain, reduce excess glucose and lipids, and improve metabolic health among pregnant females with severe obesity all of which could translate to improved perinatal health outcomes. Yet there are no clinical trials of time-restricted eating in pregnancy. The investigators aim to test the safety, feasibility, and acceptability of time-restricted eating among 80 pregnant females with severe obesity. The investigators will examine time-restricted eating safety, feasibility and acceptability (8-hr eating window in the 2nd trimester \& 10-hr eating window in the 3rd trimester), and explore its effects on weight, cardiometabolic risk markers and perinatal health outcomes vs. Standard Care. The intervention will begin at \~17 weeks gestational age and continue through admission for labor and delivery. The study will involve weekly meetings with a nutritionist, and research visits at baseline (\~17 weeks gestational age), 27-29 weeks gestational age and 35-37 weeks gestational age as well as monthly check-ins for maternal and fetal health monitoring. Maternal and neonatal data from labor and delivery will also be collected from electronic health records. Glucose will be continuously monitored for 10 days at 20 weeks gestational age and 34 weeks gestational age (optional). The goal of our work is to reduce and prevent adverse perinatal outcomes among pregnant females with severe obesity. Given the relative simplicity of time-restricted eating it can be easily disseminated in clinic demonstrating its strong potential for wide-scale public health impact.
BACKGROUND: Relapse following hematopoietic stem cell transplantation (HSCT) occurs relatively frequently and is a significant risk factor for mortality in patients with acute myeloid leukemia (AML). Early diagnosis is, therefore, of utmost importance and can provide valuable guidance for appropriate and timely intervention. Here, the diagnostic value of two molecular markers, Wilms tumor 1 (WT1) and tumor suppressor protein p53 (TP53), were studied.
METHODS AND RESULTS: Twenty AML patients undergoing HSCT participated in this investigation. Some had relapsed following HSCT, while others were in remission. Peripheral blood (PB) and bone marrow (BM) samples were collected following relapse and remission. WT1 and TP53 messenger RNA (mRNA) expression was evaluated using reverse transcription-quantitative polymerase chain reaction (RT‒qPCR). The diagnostic value of genes was evaluated by utilizing receiver-operating characteristic (ROC) curve analysis. ROC analysis showed WT1 and TP53 as diagnostic markers for relapse after HSCT in AML patients. The mRNA expression level of WT1 was elevated in individuals who experienced relapse compared to those in a state of remission (p value < 0.01). Conversely, the expression level of TP53 mRNA was lower in individuals who had relapsed compared to those in remission (p value < 0.01).
CONCLUSIONS: WT1 and TP53 possess the potential to serve as invaluable biomarkers in the identification of molecular relapse after HSCT in patients with AML. Further studies for a definitive conclusion are recommended.
Arm I (Parent Social-Cognitive Intervention Program \[P-SCIP\]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
Superior molecular vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a homologue or functional derivative thereof. Preferred spreading proteins are VP22 from HSV-1 and Marek's disease virus. The nucleic acid can encode any antigenic epitope of interest, preferably an epitope that is processed and presented by MHC class I proteins. Antigens of pathogenic organisms and cells such as tumor cells are preferred. Vaccines comprising HPV-16 E7 oncoprotein are exemplified. Also disclosed are methods of using the vaccines to induce heightened T cell mediated immunity, in particular by cytotoxic T lymphocytes, leading to protection from or treatment of a tumor.
PURPOSE: A dental clinic management method and system are provided to support exact and comfortable counseling and treatment using network chair, which has an oral camera and a monitor. CONSTITUTION: The system consists of a chair system, communication networks and medical insurance company. The chair system has not only input and output systems but also communication devices like modem and a control device. During treatment a dentist can inquiry the patient's treatment record and oral image data and after treatment the system automatically request the dentist fee to the medial insurance company. The chair has dental apparatuses, an oral camera(130), a keyboard(140), a monitor(150) and a dental server(110), which contains a processor(111), communication devices(115) and storage(120). The LCD panel and the monitor can be installed separately or unitedly like there is a monitor in the front side and an LCD panel in the rear side or vice versa. The camera is installed with a light to take a picture with low illumination. When a patient sit on the chair, the dentist can inquiry the record. If there is record or picture, the system displays them on the monitor. According to the record, the dentist consults the treatment and treats the patient. After treatment, the system makes an appointment automatically and the patient select available time.
Participants in the AC group will receive an information pamphlet about falls, Simple Exercises for Improving Balance and Preventing Falls in Older Adults, (English or Spanish version) that was developed by the CDC Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention. The topics contain information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise included what you can do to prevent falls, check for safety, postural hypotension, and chair rise exercise. The control group will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will be offered the PEER intervention when the study concludes.
BACKGROUND: To investigate the clinicopathologic characteristics, therapeutic methods, and prognosis of secretory carcinoma of salivary gland (SCSG).
METHODS: The clinicopathologic data of 13 patients with SCSG admitted to Shanxi Cancer Hospital from January 2018 to June 2023 were retrospectively analyzed, and a literature review was performed.
RESULTS: A total of eight males and five females aged 22-78 years old were enrolled, and they commonly presented with painless masses in the parotid or submandibular gland. They all underwent surgical treatment, accompanied by typical pathological examinations postoperatively. Fluorescence in situ hybridization (FISH) was conducted in seven cases, the results were all positive, and no gene fusion other than ETV6-NTRK3 was found. Two patients developed local relapse during follow-up, both of which were in the surgical area. By the end of the follow-up, 12 patients survived and one patient died.
CONCLUSIONS: SCSG is a rare low-grade malignancy with a good prognosis. Pathological and immunohistochemical characteristics are the key to secretory carcinoma (SC) diagnosis, and surgical excision is the major treatment means for SCSG. Whether to perform simultaneous cervical lymph node dissection and other adjuvant therapies should be determined based on the pathological stage and the presence or absence of high-risk factors.